5913 Results

People

  1. Ladanyi
    Ladanyi
  2. Solit
    Solit
  3. Levine
    Levine
  4. Berger
    Berger
  5. Schultz
    Schultz
  6. Arcila
    Arcila
  7. Hakimi
    Hakimi
  8. Chandarlapaty
    Chandarlapaty
  9. Zehir
    Zehir
  10. Mellinghoff
    Mellinghoff

Groups

  1. Human Oncology and Pathogenesis Program (5913)
  2. GSK Faculty (5696)
  3. Department of Medicine (4258)
  4. Department of Pathology and Laboratory Medicine (3036)
  5. Tow Center for Developmental Oncology (TCDO) (2612)
  6. Solid Tumor Oncology Division (2599)
  7. Sloan Kettering Institute Postdocs (1984)
  8. Hematologic Malignancies, Division of (1879)
  9. Center for Hematologic Malignancies (1845)
  10. Center for Molecular Imaging and Biotechnology (CMIB) (1735)
  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Journal Article (2984)
  2. Meeting Abstract (2526)
  3. Review (137)
  4. Editorial (106)
  5. Book Section (54)
  6. Research Letter (41)
  7. Guidelines (18)
  8. Correspondence (16)
  9. Miscellaneous (15)
  10. Conference Paper (13)
  11. Book Whole (3)
Groups
  1. Human Oncology and Pathogenesis Program (5913)
  2. GSK Faculty (5696)
  3. Department of Medicine (4258)
  4. Department of Pathology and Laboratory Medicine (3036)
  5. Tow Center for Developmental Oncology (TCDO) (2612)
  6. Solid Tumor Oncology Division (2599)

More Groups

People
  1. Marc Ladanyi (1326)
  2. David Solit (779)
  3. Ross Levine (774)
  4. Michael Berger (765)
  5. Nikolaus Schultz (486)
  6. Maria Arcila (426)

More People

Years
  1. 2025 (119)
  2. 2024 (359)
  3. 2023 (402)
  4. 2022 (451)
  5. 2021 (380)
  6. 2020 (457)

More Years

Publications
  1. Journal of Clinical Oncology (636)
  2. Blood (495)
  3. Cancer Research (412)
  4. Modern Pathology (299)
  5. Clinical Cancer Research (268)
  6. Laboratory Investigation (262)

More Publications

Publishers
  1. American Association for Cancer Research (871)
  2. Nature Publishing Group (757)
  3. American Society of Clinical Oncology (702)
  4. American Society of Hematology (541)
  5. Elsevier Inc. (420)
  6. Nature Research (312)

More Publishers

Results (5913)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I clinical trial of ganetespib (heat shock protein 90 inhibitor) in combination with paclitaxel and trastuzumab in human epidermal growth factor receptor-2 positive (HER2+) metastatic breast cancer
    Meeting Abstract

    Jhaveri, K.; Cadoo, K.; Chandarlapaty, S.; Teplinsky, E.; Speyer, J.; D'Andrea, G.; Patil, S.; Haque, S.; Friedman, K.; Heese, S.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • A phase I/II study of neratinib plus temsirolimus in HER2+ metastatic breast cancer reveals ongoing HER2 pathway dependence in many patients despite several lines of HER2 targeted therapy
    Meeting Abstract

    Gajria, D.; Modi, S.; Saura, C.; Sakr, R.; Solano, K.; Won, H.; Pannu, H.; Patil, S.; Lake, D.; Traina, T.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Determining the role of somatic ERa mutations in acquired hormone (or SERM) resistance
    Meeting Abstract

    Fanning, S. W.; Mayne, C.; Toy, W.; Shen, Y.; Sharma, A.; Panchamukhi, S.; Nowak, J.; Nettles, K. W.; Chandarlapaty, S.; Katzenellenbogen, J. A.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Somatic leukemogenic mutations associated with infiltrating white blood cells in breast cancer patients
    Meeting Abstract

    Comen, E. A.; Kleppe, M.; Wen, H.; Weigelt, B.; Bastian, L.; Blum, B.; Rapaport, F. T.; Keller, M.; Socci, N.; Viale, A.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Adaptive and acquired mechanisms of resistance to PI3K inhibitors
    Meeting Abstract

    Chandarlapaty, S.; Scaltriti, M.; Will, M.; Li, Z.; Bosch Campos, A.; Schwartz, S.; Rodrik-Outmezguine, V. ; Berger, M.; Baselga, J.; Rosen, N.
    Cancer Research (2015)

    Fulltext@MSK | Save
  • PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer
    Journal Article

    Majewski, I. J.; Nuciforo, P.; Mittempergher, L.; Bosma, A. J.; Eidtmann, H.; Holmes, E.; Sotiriou, C.; Fumagalli, D.; Jimenez, J.; Aura, C.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Grade-dependent metabolic reprogramming in kidney cancer revealed by combined proteomics and metabolomics analysis
    Journal Article

    Wettersten, H. I.; Hakimi, A. A.; Morin, D.; Bianchi, C.; Johnstone, M.; Donohoe, D. R.; Trott, J. F.; Abu Aboud, O.; Stirdivant, S.; Neri, B.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Partial and radical nephrectomy for unilateral synchronous multifocal renal cortical tumors
    Journal Article

    Mano, R.; Kent, M.; Larish, Y.; Winer, A. G.; Chevinsky, M. S.; Hakimi, A. A.; Sternberg, I. A.; Sjoberg, D. D.; Russo, P.
    Urology (2015)

    Fulltext@MSK | Save
  • The polycomb group protein L3MBTL1 represses a SMAD5-mediated hematopoietic transcriptional program in human pluripotent stem cells
    Journal Article

    Perna, F.; Vu, L. P.; Themeli, M.; Kriks, S.; Hoya-Arias, R. ; Khanin, R.; Hricik, T.; Mansilla-Soto, J.; Papapetrou, E. P.; Levine, R. L.; more...
    Stem Cell Reports (2015)

    Fulltext@MSK | Save
  • A retrospective evaluation of vemurafenib as treatment for BRAF-mutant melanoma brain metastases
    Journal Article

    Harding, J. J.; Catalanotti, F.; Munhoz, R. R.; Cheng, D. T.; Yaqubie, A.; Kelly, N.; McDermott, G. C.; Kersellius, R.; Merghoub, T.; Lacouture, M. E.; more...
    The Oncologist (2015)

    Fulltext@MSK | Save